Founded December 2014
Stage Business development
Investor Trendlines Incubators Israel
CEO Edit Goldberg
Escala Medical is developing the first repair device for the treatment of pelvic organ prolapse (POP) based on a nonsurgical, incision-free, mesh-free repair approach.
Escala’s novel system presents a long-overdue repair option for women with mild to moderate POP. Escala’s approach mirrors a gold standard surgery-based repair to fixate the vaginal apex to the sacrospinous ligament (SSL) in a safe, quick outpatient procedure.
See the interview with CEO Edit Goldberg on ILTV.
See the Escala Medical product animation.
Over 15 years of medical device industry experience in senior development and strategic and business development positions. DMD, Hadassah School of Dental Medicine, Hebrew University of Jerusalem; MBA, Interdisciplinary Center (IDC), Herzliya, Israel
Senior R&D engineer with vast experience in medical devices; previously, R&D head at a medical device start-up; co-inventor with more than 10 patents; specialist in mechanics and biomechanics; MSc, biomedical engineering, Technion-Israel Institute of Technology
POP is a clinical condition that affects millions of women worldwide. Associated with physical, psychological, and sexual problems, POP has a significant impact on quality of life. Treatment options are limited.
Surgeons specializing in POP repair are in immediate need of minimally invasive solutions that provide permanent relief of symptoms for the large number of women who are reluctant to use pessaries or undergo surgery.
More than 3.3 million women in the United States are diagnosed with POP. By 2050, it is estimated that the incidence of women with POP will increase by 46%. About 20% undergo surgery for POP (or UI) before the age of 80. Approximately 400,000 surgical repair procedures for POP are performed annually at an estimated direct cost of $1.4 billion.
Escala Medical believes its repair system will increase market potential as a solution for women who may be poor surgical candidates or are reluctant to undergo surgery. The Company estimates the U.S. market opportunity to exceed $600 million.